Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-5.16%
+2.20%
+0.32%
+0.85%
-0.40%
TVTX
Travere Therapeutics
$24.80
Login to see Travere Therapeutics (TVTX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Upgraded on attractively valued
Earnings are forecast to grow
Chart
$21.2 (+16.98%)
$16.47 (+50.58%)
$20.94 (+18.43%)
$18.25 (+35.89%)
TVTX has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
TVTX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
TVTX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
TVTX Street view is bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayTVTX Earnings
The TTM reflects 12-month period, providing review of TVTX financial performance.
The company financial health has moderately improved over the past year
Financial Score
VKTX
29.35
+5.27%
MRK
89.77
+0.27%
VRNA
106.80
-0.02%
NVS
132.77
+1.37%
What is TVTX current stock price?
What are TVTX stock strengths?
What risks are associated with TVTX stock?
When is TVTX next earnings report?
What is TVTX market cap and volume?
What is TVTX's current Stock IQ?
Should I buy TVTX stock right now?
Is TVTX a Strong Buy right now?
What does a 'Strong Buy' rating mean for TVTX?
What does a 'Strong Sell' rating mean for TVTX?
What factors influence TVTX's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-5.16%
+2.20%
+0.32%
+0.85%
-0.40%
TVTX
Travere Therapeutics
Current Price
$24.80
Stock Insights
Strengths
Upgraded on attractively valued
Earnings are forecast to grow
Linked to TVTX
VKTX
29.35
+5.27%
MRK
89.77
+0.27%
VRNA
106.80
-0.02%
NVS
132.77
+1.37%
Login to unlock Travere Therapeutics (TVTX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$21.2 (+16.98%)
$16.47 (+50.58%)
$20.94 (+18.43%)
$18.25 (+35.89%)
TVTX Analysts Opinion
TVTX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
TVTX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
TVTX Street view is bullish and have positive views on the near-term outlook
TVTX has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Average key support and resistance price levels.
Login to displayTVTX Earnings
The TTM data reflects the most recent 12-month period, providing overview of TVTX financial performance.
TVTX Financial Health
The company financial health has moderately improved over the past year
Financial Score
TVTX Latest Analysis
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy. FILSPARI®. (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function lossST. GALLEN ) support the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy (IgAN) Kidney Disease: Improving Global Outcomes (KDIGO) 2025 clinical practice guideline for the management of IgA Nephropathy and Immunoglobulin A
Fri Sep 26, 2025
The Analyst Verdict: Travere Therapeutics In The Eyes Of 9 Experts. During the last three months 9 analysts shared their evaluations of Travere Therapeutics (NASDAQ:) revealing diverse outlooks from ish to bearish.The following table summarizes their recent ratings shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.5310010000311000200010000The 12-month price targets analyzed by analysts offer insights with an average target of $37.89 a hi
Fri Sep 19, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
TVTX Stock trends
TVTX Stock performance
TVTX Stock analysis
TVTX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings